ClinicalTrials.gg
RecruitingNCT05943535Updated Jul 13, 2026

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

A Phase 3 interventional study of Placebo and Inhaled Treprostinil in Progressive Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by United Therapeutics. Recruiting at 165 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing treprostinil in Lung Diseases, Interstitial — 3 open to participants now, 3 under way, 3 of them phase 3. treprostinil · Lung Diseases, Interstitial.

Planned enrollment
2nd of 10
698 · median 335
Started
2023
with 1 other
Phase 3
5 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
United Therapeutics

Among the 10 studies testing treprostinil in Lung Diseases, Interstitial, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 9th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

3 of the 10 studies testing treprostinil in Lung Diseases, Interstitial are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing treprostinil in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Read the detailed description

Study RIN-PF-305 is a Phase 3, multinational, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of inhaled treprostinil in subjects with PPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.

Efficacy assessments include spirometry (forced vital capacity [FVC]), time to clinical worsening, time to first acute exacerbation of interstitial lung disease (ILD), overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.

Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.

03

Conditions studied

  • Progressive Pulmonary Fibrosis
  • Interstitial Lung Disease

Keywords

  • Treprostinil
  • PPF
  • ILD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject gives voluntary to participate in the study.
  2. Subject is ≥18 years of age, inclusive, at the time of signing informed consent.
  3. Subject has radiological evidence of pulmonary fibrosis of >10% extent on an HRCT scan in the previous 12 months (confirmed by central review).
  4. Subject has a diagnosis of PPF (other than IPF) that fulfills at least 1 of the following criteria for progression within 24 months of screening despite standard treatment of ILD, as assessed by the Investigator:

    1. decline in % predicted FVC based on ≥10% relative decline
    2. Marginal decline in % predicted FVC based on ≥5% to \<10% relative decline combined with worsening of respiratory symptoms
    3. Marginal decline in % predicted FVC based on ≥5% to \<10% relative decline combined with increasing extent of fibrotic changes on chest imaging
    4. Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging
  5. FVC ≥45% predicted at Screening (confirmed by central review).
  6. Subjects must be on 1 of the following:

    1. On nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, are planning to continue treatment through the study
    2. Not on treatment with nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, not planning to initiate either treatment during the study.

    Concomitant use of both nintedanib and pirfenidone is not permitted.

  7. Subjects treated with agents (eg, mycophenolate, methotrexate, azathioprine, oral , rituximab) need to be on treatment for at least 120 days prior to Baseline and, in the Investigator's clinical opinion, must be to treatment.
  8. Women of must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will agree to do 1 of the following:

    1. Abstain from intercourse (when it is in line with their preferred and usual lifestyle)
    2. Use 2 medically acceptable, highly effective forms of for the duration of the study, and at least 30 days after discontinuing study drug.

    i. Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable) and barrier methods (such as a condom or diaphragm) when used with a spermicide.

    Women who are successfully sterilized (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or (defined as amenorrhea for at least 12 consecutive months) are not considered to be of .

  9. Males with a partner of childbearing potential must agree to use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
  10. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or lactating.
  2. Subject has primary obstructive airway physiology (/FVC \<0.70 at Screening) or greater extent of emphysema than fibrosis on HRCT (confirmed by central review).
  3. Subject has a diagnosis of IPF.
  4. Subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  5. Subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), soluble guanylate cyclase stimulators, or activin signaling inhibitors (sotatercept) within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours prior to any study-related efficacy assessments.
  6. Subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  7. Exacerbation of ILD or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of ILD or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
  8. Subject has uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
  9. Use of any other drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
  10. Acute pulmonary embolism within 90 days prior to Baseline.
  11. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
  12. In the opinion of the Investigator, \<12 months due to ILD or a concomitant illness.
  13. Subject has received nerandomilast within 60 days prior to Baseline.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
698 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo inhaled using an ultrasonic nebulizer QID

    Drug: Placebo · Device: Treprostinil Ultrasonic Nebulizer

  • Experimental
    Inhaled Treprostinil

    Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.

    Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer

Interventions

  • DrugPlacebo

    Placebo administered QID

  • Inhaled treprostinil (6 mcg/breath) administered QID

    Also known as: Tyvaso

  • DeviceTreprostinil Ultrasonic Nebulizer

    Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

06

What researchers measure

Primary outcomes

  1. Change in Absolute FVC from Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Time to First Clinical Worsening

    Clinical worsening is monitored from randomization until 1 of the following criteria are met: death (all causes), hospitalization due to a respiratory indication, or ≥10% relative decline in % predicted FVC.

    Time frame: Baseline to Week 52

  2. Time to First Acute Exacerbation of ILD

    An exacerbation of ILD is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality.

    Time frame: Baseline to Week 52

  3. Overall Survival at Week 52

    Vital status will be assessed for all subjects at Week 52, including those who discontinue the study prematurely or who withdraw consent.

    Time frame: Week 52

  4. Change in % Predicted FVC from Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as race, sex, age, height, and weight.

    Time frame: Baseline to Week 52

  5. Change in K-BILD Questionnaire Score from Baseline to Week 52

    The K-BILD is a self-administered, 15-item questionnaire validated for patients with ILD consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms).

    Time frame: Baseline to Week 52

  6. Change in DLCO from Baseline to Week 52

    The DLCO measurement measures how well oxygen moves from the lungs to the blood.

    Time frame: Baseline to Week 52

07

Study locations

165 of 165 sites recruiting

Showing the first 100 of 165 sites across 15 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 13, 2023
StartActual
Oct 30, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05943535
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Oct 30, 2023
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

United Therapeutics Global Medical Information
Contact
clinicaltrials@unither.com
919-485-8350

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion